Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of FWD1802in Patients With ER+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

NCT06064812 is registered in ClinicalTrials.gov with Forward Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT06064812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06064812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of FWD1802in Patients With ER+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Forward Pharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 12, 2023
Completion date
March 31, 2028
Enrollment
99 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage iv, er+/her2- breast cancer, locally advanced breast cancer, metastatic breast cancer